---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000038"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T07:40:53.922738+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035

## Summary
- Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.
- Six Orange Book patents listed; three expire Sept 2029, two Feb 2033, one April 2035.
- Company intends to vigorously enforce its Qelbree intellectual property rights.
- Currently reviewing details of the ANDA filings from third parties.

## SEC filing metadata
- accession: 0001356576-25-000038
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000038/0001356576-25-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000038/supn-20250522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000038
- JSON: https://secwatch.observer/filing/0001356576-25-000038.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.